Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trialThomas Powles, Şeyda Gündüz, Yoshiaki Yamamoto et al.|Nature Medicine|2024Cited by 35